These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29807806)

  • 21. Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients.
    Iasevoli F; Fagiolini A; Formato MV; Prinzivalli E; Giordano S; Balletta R; De Luca V; de Bartolomeis A
    Psychiatry Res; 2017 Mar; 249():159-166. PubMed ID: 28104562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset.
    Fond G; Boyer L; Boucekine M; Aden LA; Schürhoff F; Tessier A; Andrianarisoa M; Berna F; Brunel L; Capdevielle D; Chereau I; Mallet J; Denizot H; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Rey R; Richieri R; Passerieux C; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Misdrahi D;
    Schizophr Res; 2017 Apr; 182():84-89. PubMed ID: 27789187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should antipsychotic medications for schizophrenia be given for a lifetime? Replication of a naturalistic, long-term, follow-up study of antipsychotic treatment.
    Glick ID; Zamora D; Kamis D; Davis JM
    CNS Spectr; 2019 Oct; 24(5):557-563. PubMed ID: 30777584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
    Faries D; Ascher-Svanum H; Phillips G; Nyhuis AW; Sugihara T; Stauffer V; Kinon BJ
    BMC Med Res Methodol; 2012 Sep; 12():142. PubMed ID: 22974273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
    Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
    Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic medication adherence and satisfaction among Palestinian people with schizophrenia.
    Sweileh WM; Ihbesheh MS; Jarar IS; Sawalha AF; Abu Taha AS; Zyoud SH; Morisky DE
    Curr Clin Pharmacol; 2012 Feb; 7(1):49-55. PubMed ID: 22299769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.
    Shafrin J; Schwartz TT; Lakdawalla DN; Forma FM
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1285-1291. PubMed ID: 27783545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
    Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
    Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China.
    Ran MS; Weng X; Chan CL; Chen EY; Tang CP; Lin FR; Mao WJ; Hu SH; Huang YQ; Xiang MZ
    Br J Psychiatry; 2015 Dec; 207(6):495-500. PubMed ID: 26382951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.
    MacEwan JP; Forma FM; Shafrin J; Hatch A; Lakdawalla DN; Lindenmayer JP
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1349-1361. PubMed ID: 27783548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China.
    Sun Y; Tong J; Feng Y; Fang H; Jiang T; Zhao L; Wang Q; Yang Y
    Front Public Health; 2022; 10():951544. PubMed ID: 36299738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unannounced telephone-based pill counts: a valid and feasible method for monitoring adherence.
    Fredericksen R; Feldman BJ; Brown T; Schmidt S; Crane PK; Harrington RD; Dhanireddy S; McReynolds J; Lober WB; Bangsberg DR; Kitahata MM; Crane HM
    AIDS Behav; 2014 Dec; 18(12):2265-73. PubMed ID: 25331265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attitudes Toward Medications and the Relationship to Outcomes in Patients with Schizophrenia.
    Campbell AH; Scalo JF; Crismon ML; Barner JC; Argo TR; Lawson KA; Miller A
    Clin Schizophr Relat Psychoses; 2018; 12(1):12-22. PubMed ID: 26218237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.
    Yalcin-Siedentopf N; Wartelsteiner F; Kaufmann A; Biedermann F; Edlinger M; Kemmler G; Rettenbacher MA; Widschwendter CG; Zernig G; Fleischhacker WW; Hofer A
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
    Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication.
    Campagna EJ; Muser E; Parks J; Morrato EH
    J Manag Care Spec Pharm; 2014 Jul; 20(7):756-66. PubMed ID: 24967528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
    Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
    Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.